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Prognostic Factors for Survival in Extensive Stage Small Cell
Lung Cancer (ED-SCLC)
The Importance of Smoking History, Socioeconomic and Marital
Statuses, and Ethnicity
Sai-Hong Ignatius Ou, MD, PhD,*† Argyrios Ziogas, PhD,†‡ and Jason A. Zell, DO, MPH*†
Background: We investigated whether independent prognostic fac-
tors for overall survival (OS) in non-small cell lung cancer such as
ethnicity, smoking history, socioeconomic, and marital statuses are
also applicable to extensive stage small cell lung cancer (ED-
SCLC).
Methods: SCLC patients diagnosed from 1991 to 2005 from 3
Southern California counties were identified. Prognostic factors for
ED-SCLC patients were evaluated by univariate and multivariate
analysis.
Results: Of the 4782 SCLC patients analyzed, only 2.5% of the
patients were never-smokers and 71.7% of patients presented with
ED-SCLC. By multivariate analysis, a positive smoking status was
a statistically significant poor prognostic factor for OS in ED-SCLC
patients (versus never-smoker; hazard ratio [HR]  1.310; p 
0.0125), in addition low socioeconomic status (SES) (from the
lowest to the highest SES score; ptrend  0.0128) and being unmar-
ried (versus married; HR 1.179; p 0.0001). Asian ethnicity was
a favorable prognostic factor in ED-SCLC (versus Caucasian; HR
0.785; p  0.0076). Female gender was another independent favor-
able prognostic factor (versus male; HR  0.823; p  0.0001).
Conclusions: A positive history of smoking, low SES, and being
unmarried are independent unfavorable prognostic factors for OS in
ED-SCLC while Asian ethnicity and female gender are independent
favorable prognostic factors for OS in ED-SCLC by multivariate
analysis.
Key Words: Extensive stage small cell lung cancer (ED-SCLC),
Asian ethnicity, Smoking status, Female gender, Socioeconomic
status, Marital status, California Cancer Registry, Prognostic factors.
(J Thorac Oncol. 2009;4: 37–43)
Lung cancer is the number one cancer cause of mortalityworldwide.1 Small cell lung cancer (SCLC) used to account
for 20 to 25% of all lung cancer but the incidence of SCLC has
been decreasing in the United States.2 SCLC has been highly
associated with smoking among the four major lung cancer
histologies.3 It is now recognized that patients with non-small
cell lung cancer (NSCLC) who are life-long nonsmokers con-
stitute a distinct clinical entity.4,5 These patients tend to be found
in women from East Asia and they tend to have better surviv-
al.5,6 We previously performed a retrospective population-based
study of NSCLC patients in three Southern California counties
and found that never-smoking status is a favorable prognostic
factor in NSCLC. In addition, Asian ethnicity is another favor-
able prognostic factor in NSCLC patients independent of smok-
ing status.7 Other independent favorable prognostic factors iden-
tified are high socioeconomic status (SES) and being married.7
In this report we investigated the proportion of never-smokers
with SCLC and whether smoking status is an independent
prognostic factor in SCLC similar to NSCLC. We further in-
vestigated whether Asian ethnicity, SES, and marital status are
independent prognostic factors similar to our findings in NSCLC
patients.
PATIENTS AND METHODS
Population
This is a retrospective study involving analysis of data
from the Cancer Surveillance Programs of Orange, San Diego
and Imperial counties in southern California covering an area
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with estimated population of 6.2 million. SCLC patients
diagnosed between 1991 to 2005 who had complete fol-
low-up data were included in the study. Tumor site was
abstracted as previously described.8 The ICD-O-3 histology
codes 8041 to 8045 were designated as SCLC.9 Limited
disease (LD-SCLC) is defined as local and regional disease
stage and extensive disease (ED-SCLC) is defined as distant
disease stage according to Surveillance, Epidemiology, and
End Results (SEER) summary staging. Patients with un-
known or missing staging information were excluded in the
analysis. Patient demographic data were abstracted using
SEER codes. The measurement of SES used in this analysis
was a composite measure using California Cancer Registry
(CCR) and census data as previously described.10 Radiation
therapy and surgical techniques were abstracted using SEER
codes. Chemotherapy given during the first course of therapy
was ascertained using CCR codes.
Smoking status was abstracted by examining text files
of individual patient database as previously described.8 Pa-
tients with any documented history of smoking were classi-
fied as smokers. Patients with documentation of no smoking
history were classified as never-smokers. Patients lacking
documented information on smoking history were listed as
unknown.
Statistical Analyses
Comparisons of demographic, clinical, and pathologic
variables were made for SCLC patients, using Pearson 2
statistic or Fisher’s exact test for nominal variables and
Student t test for continuous variables. Univariate survival
rate analyses were estimated using the Kaplan and Meier
method, with comparisons made between groups by the
log-rank test. Cox proportional hazards modeling using time
since diagnosis were performed. All statistical analyses were
conducted using SAS 9.1 statistical software (SAS Institute,
Inc., Cary, NC). Statistical significance was assumed for a
two-tailed p value less than 0.05.
Ethical Considerations
This research study was approved by the University of
California Irvine Institutional Review Board (#2004-3971
and #2007-6078).
RESULTS
Characteristic of SCLC Patients
Between 1991 and 2005 a total of 4782 SCLC patients
whose staging status were available were analyzed of which
71.7% of these patients presented with ED-SCLC. Only 2.5%
of the patients (n  120) were never-smokers. The median
time of follow-up for LD-SCLC patients was 12 months
(95% confidence interval: 1–77 months) and 5 months for
ED-SCLC patients (95% CI: 0–25 months). We only per-
formed analysis of prognostic factors in ED-SCLC patients
because of the limited numbers of LD-SCLC patients. The
clinical, pathologic, and demographic characteristics of ED-
SCLC patients are shown in Table 1.
Age at Diagnosis
The median age of diagnosis of smokers with ED-
SCLC was 68 years compared with 73 years for never-
smokers with ED-SCLC (p  0.0001).
TABLE 1. Clinicopathologic Characteristics of the Extensive
Stage Small-Cell Lung Cancer Patients (ED-SCLC)
Extensive Disease (ED-SCLC) (%)
n 3428
Median age 68
Smoking status
Yes 2539 (74.1)
No 93 (2.7)
Unknown 796 (23.2)
Ethnicity
Caucasian 2958 (86.3)
Hispanic 234 (6.8)
Asian 144 (4.2)
African American 85 (2.5)
Other 7 (0.2)
Gender
Male 1830 (53.4)
Female 1598 (46.6)
Age
0–39 19 (0.6)
40–49 134 (3.9)
50–59 587 (17.1)
60–69 1149 (33.5)
70–79 1158 (33.8)
80 381 (11.1)
Socioeconomic status (SES)
SES1 353 (10.3)
SES2 614 (17.9)
SES3 828 (24.2)
SES4 894 (26.1)
SES5 739 (21.6)
Marital status
Married 1854 (54.1)
Unmarried 1503 (43.8)
Unknown 71 (2.1)
Chemotherapy
Yes 2359 (68.8)
No 1061 (31.0)
Unknown 8 (0.2)
Radiation
Yes 1204 (35.1)
No 2224 (64.9)
Surgery
Lobectomy 5 (0.1)
Other surgeries 31 (0.9)
No 3390 (98.9)
Unknown 2 (0.1)
ED-SCLC, extensive stage small-cell lung cancer patients; SES, socioeconomic
status; n, number.
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Socioeconomic Status (SES)
The distribution of clinicopathologic characteristics
of ED-SCLC patients among the five SES quintiles is
shown in Table 2. There were significantly more Hispanic,
African American, and unmarried patients in the lower
SES quintiles.
Marital Status
The distribution of clinicopathologic characteristics of
ED-SCLC according to marital status is shown in Table 3.
There were significantly more females, more African Amer-
icans, more patients 80 years old, less treatment received
(chemotherapy, radiation, surgery), and with lower SES in
ED-SCLC patients who are unmarried.
Univariate Survival Analysis
Stage
The 1-year, 2-year, and median overall survival (OS) for
LD-SCLC patients were 51.9%, 23.9%, and 13 months which
was significantly better than the corresponding values for ED-
SCLC patients (20.3%, 5.7%, and 5 months; p  0.0001).
Smoking Status
There was no statistical significant difference in the
1-year, 2-year, and median OS of never-smokers with ED-
SCLC (21.9%, 6.9%, and 6 months respectively) when com-
pared with the 1-year, 2-year, and median OS of smokers
with ED-SCLC (20.9%, 5.5%, and 6 months respectively;
p  0.7455).
TABLE 2. Distribution of SES Quintiles Among ED-SCLC Patients
SES1 (%) SES2 (%) SES3 (%) SES4 (%) SES5 (%) p
n 353 614 828 894 739
Smoking status
Yes 257 (72.8) 449 (73.1) 616 (74.4) 660 (73.8) 557 (75.4) 0.6678
No 6 (1.7) 13 (2.1) 25 (3.0) 29 (3.2) 20 (2.7)
Unknown 90 (25.5) 152 (24.8) 187 (23.5) 205 (22.9) 162 (21.9)
Gender
Male 206 (58.4) 315 (51.3) 450 (54.3) 474 (53.0) 385 (52.1) 0.2464
Female 147 (41.6) 299 (48.7) 378 (45.7) 420 (47.0) 254 (47.9)
Ethnicity
African American 34 (9.6) 21 (3.4) 21 (2.5) 6 (0.7) 3 (0.4) 0.0001
Asian 20 (5.7) 29 (4.7) 48 (5.8) 25 (2.8) 22 (3.0)
Caucasian 219 (62.0) 507 (82.6) 717 (86.6) 825 (92.3) 690 (93.4)
Hispanic 78 (22.1) 54 (8.8) 40 (4.8) 38 (4.3) 24 (3.3)
Other/unknown 2 (0.6) 3 (0.5) 2 (0.2) 0 (0.0) 0 (0.0)
Age of diagnosis
0–39 0 (0.0) 3 (0.5) 7 (0.8) 6 (0.7) 3 (0.4) 0.1265
40–49 15 (4.2) 29 (4.7) 23 (2.8) 38 (4.3) 29 (3.9)
50–59 62 (17.6) 105 (17.1) 133 (16.1) 163 (18.2) 124 (16.8)
60–69 121 (34.3) 207 (33.7) 302 (36.5) 275 (30.8) 244 (33.0)
70–79 123 (34.8) 201 (32.7) 278 (33.6) 306 (34.2) 250 (33.8)
80 49 (9.1) 69 (11.2) 85 (10.3) 106 (11.9) 89 (12.0)
Marital status
Married 150 (42.5) 310 (50.5) 415 (50.1) 529 (59.2) 450 (60.9) 0.0001
Unmarried 195 (55.2) 289 (47.1) 393 (47.5) 349 (39.0) 277 (37.5)
Unknown 8 (2.3) 15 (2.4) 20 (2.4) 16 (1.8) 12 (1.6)
Chemistry
Yes 231 (65.4) 417 (67.9) 556 (67.2) 634 (70.9) 521 (70.5) 0.1698
No 121 (34.3) 196 (31.9) 272 (32.9) 258 (28.9) 214 (29.0)
Unknown 1 (0.3) 1 (0.2) 0 (0.0) 2 (0.2) 4 (0.5)
Radiation
Yes 115 (32.6) 200 (32.6) 281 (33.9) 320 (35.8) 288 (39.0) 0.0830
No 238 (67.4) 414 (67.4) 547 (66.1) 574 (64.2) 451 (61.0)
Surgery
Yes 2 (0.6) 9 (1.5) 8 (1.0) 12 (1.3) 5 (0.7) 0.3191
No 351 (99.4) 605 (98.5) 820 (99.0) 880 (98.4) 734 (99.3)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.2) 0 (0.0)
ED-SCLC, extensive stage small-cell lung cancer patients; SES, socioeconomic status; n, number.
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Gender
The 1-year, 2-year, and median OS for female ED-
SCLC patients were 22.7%, 6.8%, and 6 months respectively
were statistically significant better than the corresponding
numbers for male ED-SCLC patients (18.2%, 4.8%, and 5
months respectively; p  0.0042).
Ethnicity
The OS of Asian ED-SCLC patients was statistically
significant better than African American, Caucasian, and
Hispanic ED-SCLC patients (p  0.0438) (Figure 1).
Surgery
The survival of ED-SCLC patients who received sur-
gical interventions did not differ significantly from ED-SCLC
patients who did not receive surgical interventions (p 
0.4924) as only 31 ED-SCLC patients received surgeries
(0.9%) and only 5 of 3428 ED-SCLC patients received
lobectomy (0.1%).
Chemotherapy
The 1-year, 2-year, and median OS of ED-SCLC pa-
tients who received chemotherapy were 27.4%, 7.7%, and 8
months and were significantly better than ED-SCLC patients
who did not receive chemotherapy (4.3%, 1.1%, and 1 month
respectively; p  0.0001).
Radiation
The 1-year, 2-year, and median OS of ED-SCLC pa-
tients who received radiation were 27.8%, 9.3%, and 8
months and were significantly better than ED-SCLC patients
who did not receive radiation (16.2%, 3.8%, and 4 months
respectively; p  0.0001).
Socioeconomic Status (SES)
The 1-year, 2-year, and median OS for ED-SCLC
patients in the highest SES quintile (SES5) were 28.0%,
6.2%, and 7 months. For ED-SCLC patients in the SES4
quintile, the corresponding values were 17.7%, 5.1%, and 6
months respectively. For ED-SCLC patients in the SES3
quintile, the values were 17.8%, 5.8%, and 5 months respec-
tively. For ED-SCLC patients in the SES2 quintile, the values
were 18.7%, 5.0%, and 5 months respectively. For ED-SCLC
patients in the lowest SES quintile (SES1), the values were
19.2%, 7.0%, and 4 months respectively. The difference in
survival of ED-SCLC patients among the 5 SES quintiles is
statistically significant (p  0.0011).
Marital Status
The 1-year, 2-year, and median OS for ED-SCLC
patients who were married were 23.1%, 6.7%, and 7 months
respectively were statistically significant improved than ED-
SCLC patients who were not married (16.8%, 4.4%, and 4
months respectively; p  0.0001).
Multivariate Survival Analysis
A positive history of smoking (versus never-smoker,
hazard ratio [HR]  1.310; p  0.0125) was a significant
independent unfavorable prognostic factor for OS in ED-
SCLC. Being unmarried (versus married, HR  1.179; p 
0.0001) was another independent unfavorable prognostic fac-
tor. Low SES was another significant unfavorable prognostic
factor (from lowest to highest SES score; HR 0.965; p trend
0.0128). However, Asian ethnicity was an independent favor-
able prognostic factor (versus Caucasian; HR  0.785; p 
0.0076). Other favorable prognostic factors were female gen-
der, younger age of diagnosis, and treatment (radiation,
chemotherapy) (Table 4).
TABLE 3. Distribution of Marital Status Among ED-SCLC
Patients
Married
(%)
Unmarried
(%)
Unknown
(%) p
n 1854 1503 71
Smoking status
Yes 1367 (73.7) 1122 (74.7) 50 (70.4) 0.3480
No 56 (3.0) 37 (2.5) 0 (0.0)
Unknown 431 (23.2) 344 (22.9) 21 (29.6)
Gender
Male 1204 (64.9) 597 (39.7) 29 (40.8) 0.0001
Female 650 (35.1) 906 (60.3) 42 (59.2)
Ethnicity
African American 34 (1.8) 50 (3.3) 1 (1.4) 0.0042
Asian 99 (5.3) 42 (2.8) 3 (4.2)
Caucasian 1591 (85.8) 1308 (87.0) 59 (83.1)
Hispanic 126 (6.8) 102 (6.8) 6 (8.5)
Other/unknown 4 (0.2) 1 (0.1) 2 (2.8)
Age of diagnosis
0–39 9 (0.5) 10 (0.7) 0 (0.0) 0.0001
40–49 70 (3.8) 60 (4.0) 4 (5.6)
50–59 327 (17.6) 245 (16.3) 15 (21.1)
60–69 697 (37.6) 435 (28.9) 17 (23.9)
70–79 616 (33.2) 519 (34.5) 23 (32.4)
80 135 (7.3) 234 (15.6) 12 (16.9)
Socioeconomic status
(SES)
SES1 150 (8.1) 195 (13.0) 8 (11.3) 0.0001
SES2 310 (16.7) 289 (19.2) 15 (21.1)
SES3 415 (22.4) 393 (26.2) 20 (28.2)
SES4 529 (28.5) 349 (23.2) 16 (22.5)
SES5 450 (24.3) 277 (18.4) 12 (16.9)
Chemistry
Yes 1365 (73.6) 956 (63.6) 38 (53.5) 0.0001
No 485 (26.2) 543 (36.1) 33 (46.5)
Unknown 4 (0.2) 4 (0.3) 0 (0.0)
Radiation
Yes 717 (38.7) 467 (31.1) 20 (28.2) 0.0001
No 1137 (61.3) 1036 (68.9) 51 (71.8)
Surgery
Yes 21 (1.1) 12 (0.8) 3 (4.2) 0.0331
No 1833 (98.9) 1489 (99.1) 68 (95.8)
Unknown 0 (0.0) 2 (0.1) 0 (0.0)
ED-SCLC, extensive stage small-cell lung cancer patients; SES, socioeconomic
status; n, number.
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DISCUSSION
In this report, we confirmed that SCLC is highly asso-
ciated with tobacco smoking as only 2.5% of the patients in
the study were never-smokers. We found that never-smokers
with SCLC were statistically significant older than smokers
with SCLC. Additionally, a positive smoking history is an
independent poor prognostic factor for OS in ED-SCLC
patients by multivariate analysis despite a 5-year increase in
the median age of diagnosis for never-smokers. Wolf et al.11
have also shown that never-smokers had higher median
survival (13.6 months versus 9.9 months) and 2-year survival
rate (17% versus 7%) than smokers with SCLC, and that
positive history is an independent unfavorable prognostic
factor for both male and female SCLC patients by Cox
regression analysis. The study included a substantial number
of never-smokers (n  63; 8.3%),11 in contrast the lack of a
prognostic effect of smoking history in SCLC reported by
others are likely due to the small numbers of never-smokers:
7 (9.2%),12 10 (9.1%),13 and 5 (6.6%) respectively.14 Lassen
et al.15 reported that only 1 of 1714 SCLC patients was a
never-smoker and of the 60 long-term survivors (5 years)
none were never-smokers. Smoking causes many more ge-
netic disruptions in smokers16 and likely result in more
comorbidities in patients. Given the very low percentage of
never-smokers with SCLC further studies are required to
distinguish whether SCLC in never-smokers is a distinct
clinical entity as in the case of NSCLC4,5 or as a result of
passive exposure to tobacco.
Second, we showed that Asian ethnicity is a favorable
prognostic factor in ED-SCLC by both univariate and multi-
variate analyses. There is paucity in the literature about the
significance of ethnicity in the survival outcome in SCLC.
Albain et al.17 using Southwest Oncology Group (SWOG)
database reported that Caucasian is an independent favorable
prognostic factor in survival in LD-SCLC but the significance
TABLE 4. Cox Multivariate Analysis of ED-SCLC Patients
Variable HR 95% CI p
Smoking
No 1.00
Yes 1.310 (1.060–1.618) 0.0125
Unknown 1.234 (0.991–1.537) 0.0625
Ethnicity
Caucasian 1.00
African American 0.973 (0.776–1.221) 0.8154
Asian 0.785 (0.657–0.938) 0.0076
Hispanic 0.917 (0.796–1.055) 0.2253
Other 2.934 (1.216–7.082) 0.0166
Gender
Male 1.00
Female 0.823 (0.766–0.884) 0.0001
Age 1.012 (1.008–1.016) 0.0001
Socioeconomic status (SES)a 0.965 (0.939–0.993) 0.0128
Marital statusb
Married 1.00 0.0001
Unmarriedc 1.179 (1.095–1.269)
Chemotherapyb
No 1.00 0.0001
Yes 0.335 (0.309–0.364)
Radiation
No 1.00 0.0001
Yes 0.721 (0.670–0.776)
Surgeryb
No 1.00 0.1700
Yes 0.791 (0.565–1.106)
a Analyzed as a continuous variable from the lowest to the highest SES score.
b Unknown included in Cox proportional hazards model but not shown.
c Unmarried (single, separated, divorced, widowed).
HR, hazard ratio; CI, confidence interval; SES, socioeconomic status; ED-SCLC,
extensive stage small-cell lung cancer patients.
FIGURE 1. Overall survival curves
of 4 major ethnicities with exten-
sive stage small cell lung cancer
(ED-SCLC).
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disappears if only more recent clinical trials were included.
Blackstock et al.18 have previously showed that African
American patients had similar survival as non-African Amer-
ican patients in ED-SCLC. There were only 12 Hispanic and
8 Asian patients in that study thus the contribution of Asian
or Hispanic ethnicity cannot be adequately determined. Our
conclusion is strengthened by the inclusion of SES and
marital status in the Cox multivariate analysis. We have
previously shown in stage one NSCLC lung cancer that
African American and Hispanic patients had poorer survival
as compared with Caucasians but this survival disadvantage
disappeared after SES and marital status were factored in the
Cox proportional hazards model.19 Studies of SCLC patients
from Asian countries indicated Asian SCLC patient had
similar clinicopathologic characteristics and survival out-
come as Western SCLC patients, however, there were no
direct comparison.12,20 A potential explanation is the ethnic
variability in the genetic polymorphism of drug metabolizing
genes. Irinotecan in combination with platinum had been
shown to confer superior OS in the treatment of first line
ED-SCLC from randomized trials performed in Japan21 but
not in the United States.22,23 The active metabolite of irino-
tecan, SN-38, is inactivated by glucuronidation by the en-
zyme UGT1A1. There is well known racial variability in the
UGT1A1 promoter from single nucleotide polymorphism
leading to varying level of expression of the enzyme and
resultant toxicities and potential efficacies from irinote-
can.24,25 Our results should be considered as preliminary and
hypothesis-generating and will require validation from other
population-based epidemiologic and molecular studies and/or
clinical trials.
Third, this is the first report to show SES is an inde-
pendent prognostic factor in ED-SCLC. There were signifi-
cantly more Hispanic and African American patients in the
lower SES quintiles, and significantly more unmarried pa-
tients in the lower SES with 55.2% of patients in the lowest
SES quintile (SES1) being unmarried compared with only
37.5% of the patients in the highest SES quintile (SES5)
(Table 2). Our report also showed that marital status is an
independent prognostic factor in ED-SCLC. Comparing to
married patients, unmarried patients consisted of significantly
more females, more African Americans, more patients who
were80 years old, and more patients in the lower SES. Also
fewer unmarried patients received chemotherapy or radiation
for the treatment of their ED-SCLC and this observation may
partially account for the poorer survival for patients who were
unmarried as SCLC are very responsive to chemotherapy
and/or radiation. All these prognostic factors were included
in the Cox multivariate model but SES and marital status
remained as independent prognostic factors. This observa-
tion is similar to our report on stage one NSCLC where
SES and marital status remained as independent prognostic
factors after inclusion in multivariate analysis.11 Further
studies will be needed to investigate and understand the
role of these two social factors in determining the survival
outcome in ED-SCLC.
Finally, we identified female gender, younger age at
diagnosis, radiation, and chemotherapy treatment as favor-
able prognostic factors in ED-SCLC. It has been well-estab-
lished that female SCLC patients survived longer than male
SCLC patients18,26–33 and it has been shown that female
SCLC patients had higher complete and overall response
rates to chemotherapy12,26,30–33 though females also devel-
oped more treatment-related toxicities.32
Limitations of this study include there was no central
pathologic review and about 40% patients had incomplete
TNM staging data. The time period included in this study is
over 15 years but there is essentially no major change in the
treatment of ED-SCLC. There was also no information in
CCR on the tumor marker lactate dehydrogenase16,18,31,33–35
or performance status16,26–35 which has been shown to be an
independent important prognostic factor in many studies.
Moreover, the site and number of metastasis in ED-SCLC is
not coded thus we are not able to include the number of
metastatic sites into the Cox model as both brain metastasis
and the number of metastatic sites have been shown to be
prognostic.18,26,27,31,35 Thus, the independence of Asian eth-
nicity, SES, and marital status as prognostic factors are
significant but hypothesis-generating and should be validated
in future studies where lactate dehydrogenase, performance
status, and number of metastatic sites are also incorporated in
the multivariate analysis. Lastly, we were unable to determine
whether patients had received any prophylactic cranial irra-
diation which has been shown to increase OS in LD-SCLC36
and ED-SCLC.37 In summary, we have shown that a positive
history of smoking is an unfavorable prognostic factor for OS
in ED-SCLC. Other independent prognostic factors identified
in this study such as Asian ethnicity, SES, and marital status
will require future validation and investigations.
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